Serum NY-ESO-1 antibody as a predictive biomarker for postoperative recurrence of gastric cancer: a multicenter prospective observational study

Background No reliable marker has been identified to predict postoperative recurrence of gastric cancer. We designed a clinical trial to investigate the utility of serum NY-ESO-1 antibody responses as a predictive marker for postoperative recurrence in gastric cancer. Methods A multicenter prospecti...

Full description

Saved in:
Bibliographic Details
Published in:British journal of cancer 2024-04, Vol.130 (7), p.1157-1165
Main Authors: Saito, Takuro, Kurokawa, Yukinori, Fujitani, Kazumasa, Kawabata, Ryohei, Takeno, Atsushi, Mikami, Jota, Endo, Shunji, Matsuyama, Jin, Akamaru, Yusuke, Hirota, Masashi, Kishi, Kentaro, Urakawa, Shinya, Yamamoto, Kei, Tanaka, Koji, Takahashi, Tsuyoshi, Oka, Mikio, Wada, Hisashi, Eguchi, Hidetoshi, Doki, Yuichiro
Format: Article
Language:English
Subjects:
631/250/21/2153
631/250/2520
631/67/1504/1829
631/67/1857
Antibodies
Antigens, Neoplasm
Biomarkers
Biomedical and Life Sciences
Biomedicine
Cancer Research
Clinical trials
Drug Resistance
Epidemiology
Gastric cancer
Humans
Membrane Proteins
Molecular Medicine
Multivariate analysis
Oncology
Prospective Studies
Stomach Neoplasms - surgery
Tumor Suppressor Protein p53
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background No reliable marker has been identified to predict postoperative recurrence of gastric cancer. We designed a clinical trial to investigate the utility of serum NY-ESO-1 antibody responses as a predictive marker for postoperative recurrence in gastric cancer. Methods A multicenter prospective study was conducted between 2012 and 2021. Patients with resectable cT3-4 gastric cancer were included. Postoperative NY-ESO-1 and p53 antibody responses were serially evaluated every 3 months for 1 year in patients with positive preoperative antibody responses. The recurrence rate was assessed by the positivity of antibody responses at 3 and 12 months postoperatively. Results Among 1001 patients, preoperative NY-ESO-1 and p53 antibody responses were positive in 12.6% and 18.1% of patients, respectively. NY-ESO-1 antibody responses became negative postoperatively in non-recurrent patients (negativity rates; 45% and 78% at 3 and 12 months, respectively), but remained positive in recurrent patients (negativity rates; 9% and 8%, respectively). p53 antibody responses remained positive in non-recurrent patients. In multivariate analysis, NY-ESO-1 antibody positivity at 3 months ( P   
ISSN:0007-0920
1532-1827
DOI:10.1038/s41416-023-02540-3